A strong dose from Pfizer - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

A strong dose from Pfizer

Sep 22, 2000

Despite apprehensions about the intentions of the management, after the setting up of a 100% subsidiary, Pfizer continues to report healthy growth rates.

(Rs m) 3QFY00 3QFY01 Change
Sales 885 1,003 13.4%
Other Income 17 21 19.9%
Expenditure 727 793 9.1%
Operating Profit (EBDIT) 158 210  
Operating Profit Margin (%) 17.8% 20.9%  
Interest 3 1 -66.7%
Depreciation 18 13 -31.1%
Profit before Tax 154 217 41.1%
Other Adjustments      
Tax 55 88  
Profit after Tax/(Loss) 99 129 30.7%
Net profit margin (%) 11.2% 12.9%  
Earnings per share* 16.84 22.01  
(annualised)      

The company has delivered a 30% increase in post–tax profits in the third quarter of the current year, despite Becousules (its B–complex vitamin) being brought under price control. (Becousules contributes around 20% to the company’s turnover and the National Pharmaceutical Pricing Authority has reduced its prices by 30% in the current year.)

The company’s topline grew by 13% over the corresponding period of last year. The stock quotes at Rs 606, which implies an earning multiple of 27.5 times.

Equitymaster requests your view! Post a comment on "A strong dose from Pfizer". Click here!

  

More Views on News

PFIZER Announces Quarterly Results (2QFY21); Net Profit Down 14.8% (Quarterly Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

For the quarter ended September 2020, PFIZER has posted a net profit of Rs 1 bn (down 14.8% YoY). Sales on the other hand came in at Rs 6 bn (up 5.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER 2017-18 Annual Report Analysis (Annual Result Update)

Jan 1, 2019 | Updated on Jan 1, 2019

Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

Stocks that Could Shine More than Gold After Diwali (Profit Hunter)

Nov 17, 2020

If the markets become volatile over the next few months, do this.

How the New Margins Will Impact You (Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

How to Build the Best Trading System (Fast Profits Daily)

Nov 20, 2020

In this video, I'll show you how to make the best trading system.

An Eraser and Some Pencils (The Honest Truth)

Nov 17, 2020

Ajit Dayal on the road ahead for the world after covid.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Nov 27, 2020 (Close)

TRACK PFIZER

PFIZER - TEVA PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS